These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22936671)

  • 21. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
    Asselah T; Marcellin P
    Liver Int; 2012 Feb; 32 Suppl 1():88-102. PubMed ID: 22212578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telaprevir for the treatment of chronic hepatitis C infection.
    Muir AJ
    Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
    Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
    J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
    [No Abstract]   [Full Text] [Related]  

  • 24. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N; Zeuzem S
    Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of emerging therapies for the treatment of chronic hepatitis C.
    Ilyas JA; Vierling JM
    Clin Liver Dis; 2011 Aug; 15(3):515-36. PubMed ID: 21867934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What are the management issues for hepatitis C in dialysis patients?: hepatitis C virus infection and its treatment in patients with end-stage renal disease.
    Rostaing L; Alric L; Izopet J; Kamar N
    Semin Dial; 2014; 27(5):451-5. PubMed ID: 25204878
    [No Abstract]   [Full Text] [Related]  

  • 27. [New agents for the treatment of hepatitis C].
    Buti M; Homs M
    Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):147-50. PubMed ID: 22118805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New genetic discoveries and treatment for hepatitis C.
    Pacanowski M; Amur S; Zineh I
    JAMA; 2012 May; 307(18):1921-2. PubMed ID: 22570460
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
    Kwo PY; Lawitz EJ; McCone J; Schiff ER; Vierling JM; Pound D; Davis MN; Galati JS; Gordon SC; Ravendhran N; Rossaro L; Anderson FH; Jacobson IM; Rubin R; Koury K; Pedicone LD; Brass CA; Chaudhri E; Albrecht JK;
    Lancet; 2010 Aug; 376(9742):705-16. PubMed ID: 20692693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New therapeutic options in chronic hepatitis C virus infection].
    Hunyady B
    Orv Hetil; 2011 May; 152(22):887-97. PubMed ID: 21565757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis in 2010: the dawn of a new era in HCV therapy.
    Ciesek S; Manns MP
    Nat Rev Gastroenterol Hepatol; 2011 Feb; 8(2):69-71. PubMed ID: 21293503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):57-9. PubMed ID: 21778964
    [No Abstract]   [Full Text] [Related]  

  • 33. [Chronic hepatitis C: improved cure rates with new approved medications].
    Grammatikos G; Vermehren J; Zeuzem S
    MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():65-9; quiz 70. PubMed ID: 22916428
    [No Abstract]   [Full Text] [Related]  

  • 34. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Conclusions].
    Pineda JA
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():49-50. PubMed ID: 24063903
    [No Abstract]   [Full Text] [Related]  

  • 36. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
    Wyles DL; Gutierrez JA
    J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients.
    Fontaine H; Pol S
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S59-63. PubMed ID: 22248696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
    Zeuzem S
    J Hepatol; 2008 Aug; 49(2):157-9. PubMed ID: 18554745
    [No Abstract]   [Full Text] [Related]  

  • 39. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New treatments for chronic hepatitis C virus infection.
    Corouge M; Pol S
    Med Mal Infect; 2011 Nov; 41(11):579-87. PubMed ID: 21764234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.